Search | Clinical Trials Finder

Conditions: Healthy
Interventions: Placebo, RSV preF Protein 50 mcg, RSV preF Protein 150 mcg, Ad26.RSV.preF 1*10^11 vp, Mixture of Ad26.RSV.preF 5*10^10 vp Plus RSV preF Protein 50 mcg, Mixture of Ad26.RSV.preF 5*10^10 vp Plus RSV preF Protein 150 mcg, Mixture of Ad26.RSV.preF 1*10^11 vp Plus RSV preF Protein 50 mcg, Mixture of Ad26.RSV.preF 1*10^11 vp Plus RSV preF Protein 150 mcg, Selected Regimen; Biological
Lead sponsor: Janssen Vaccines & Prevention B.V.; Industry
Eligibility: 60 Years and older
Enrollment: 669 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2022
U.S. locations: 6
States / cities: Huntsville, Alabama • San Diego, California • Melbourne, Florida + 3 more

Conditions: Healthy Volunteers
Interventions: TAK-951, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 2
States / cities: Lenexa, Kansas • Salt Lake City, Utah

Conditions: Stiff-Person Syndrome
Interventions: Intravenous Immunoglobulins, Human, Placebos; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Epilepsy, Dravet Syndrome
Interventions: GWP42003-P, Placebo Control; Drug
Lead sponsor: Jazz Pharmaceuticals; Industry
Eligibility: 2 Years to 18 Years
Enrollment: 199 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 23
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 20 more

Conditions: Chronic Kidney Disease, Type 2 Diabetes
Interventions: Finerenone (Kerendia, BAY94-8862), Sodium-glucose cotransporter-2 inhibitors (SGLT2i); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 17,847 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Whippany, New Jersey

Conditions: Ulcerative Colitis
Interventions: Andecaliximab, Placebo to match Andecaliximab; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 6
States / cities: Monroe, Louisiana • Bethesda, Maryland • Chesterfield Township, MI 48047, Michigan + 3 more

Conditions: Acute Hereditary Angio Edema
Interventions: OCTA-C1-INH, Placebo; Drug · Other
Lead sponsor: Octapharma; Industry
Eligibility: 2 Years and older
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 3
States / cities: Centennial, Colorado • Farmington Hills, Michigan • Toledo, Ohio

Conditions: Healthy
Interventions: Niclosamide, Placebo; Drug
Lead sponsor: NeuroBo Pharmaceuticals Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Cypress, California

Conditions: Bipolar Disorder
Interventions: Simvastatin, Placebo; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 65 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Functional Constipation
Interventions: Linaclotide, Placebo; Drug
Lead sponsor: Allergan; Industry
Eligibility: 2 Years to 5 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 18
States / cities: Birmingham, Alabama • Hot Springs, Arkansas • Little Rock, Arkansas + 15 more

Conditions: Hypertriglyceridemia, Cardiovascular Diseases
Interventions: ISIS 678354, Placebo; Drug
Lead sponsor: Akcea Therapeutics; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 114 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 24
States / cities: Cottonwood, Arizona • Little Rock, Arkansas • Carmichael, California + 21 more

Conditions: Inflammation
Interventions: Difluprednate, Placebo; Drug
Lead sponsor: Sirion Therapeutics, Inc.; Industry
Eligibility: 2 Years and older
Enrollment: 219 participants
U.S. locations: 1
States / cities: Washington, Missouri

Conditions: Anti-3-hydroxy-3-methylglutaryl-CoA Reductase (HMGCR) Immune-Mediated Necrotizing Myopathy
Interventions: Intravenously administered pooled human immunoglobulin (IVIG); Biological
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 16 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 5
States / cities: Birmingham, Alabama • Baltimore, Maryland • Pittsburgh, Pennsylvania + 2 more

Conditions: Systemic Lupus Erythematosus, Lupus Erythematosus, Systemic
Interventions: TAK-079, TAK-079 Placebo; Drug
Lead sponsor: Millennium Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 19
States / cities: Anniston, Alabama • Birmingham, Alabama • La Jolla, California + 15 more

Conditions: Healthy Volunteers
Interventions: TAK-951 Placebo, TAK-951; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 128 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Glendale, California

Conditions: Food Allergy
Interventions: Low dose ADP101, High dose ADP101, Pooled Placebo; Biological
Lead sponsor: Alladapt Immunotherapeutics, Inc.; Industry
Eligibility: 4 Years to 55 Years
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 15
States / cities: Mission Viejo, California • Rolling Hills Estates, California • San Diego, California + 12 more

Conditions: Systemic Lupus Erythematosus (SLE)
Interventions: AKBM-3031, Placebo; Dietary Supplement · Other
Lead sponsor: Aker BioMarine Human Ingredients AS; Industry
Eligibility: 18 Years and older
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 15
States / cities: Birmingham, Alabama • Beverly Hills, California • Orange, California + 12 more

Conditions: Nervous System Disease, Genetic Syndrome
Interventions: EryDex Low dose DSP, EryDex High dose DSP, Pooled Placebo; Drug
Lead sponsor: Quince Therapeutics S.p.A.; Industry
Eligibility: 6 Years and older
Enrollment: 176 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 4
States / cities: Los Angeles, California • Baltimore, Maryland • Cincinnati, Ohio + 1 more

Conditions: Gastroenteritis Norovirus
Interventions: Norovirus GII.4 Challenge Pool CIN-1, Placebo; Biological · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 49 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Cardiac Surgery, Cardiopulmonary Bypass
Interventions: AT-III (Human), Placebo; Biological · Other
Lead sponsor: Grifols Therapeutics LLC; Industry
Eligibility: 18 Years and older
Enrollment: 425 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 41
States / cities: Orange, California • San Francisco, California • Stanford, California + 36 more

Conditions: Cystic Fibrosis
Interventions: MRT5005, Normal saline; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 16
States / cities: Birmingham, Alabama • Denver, Colorado • Gainesville, Florida + 13 more

Conditions: HIV Infections
Interventions: chloroquine phosphate, Placebo; Drug
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years to 65 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Healthy Volunteers
Interventions: AZD1163, Placebo; Biological · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 108 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 2
States / cities: Glendale, California • Brooklyn, Maryland

Conditions: Chronic Lymphocytic Leukemia, Hypogammaglobulinemia
Interventions: Panzyga, Placebo; Biological · Other
Lead sponsor: Octapharma; Industry
Eligibility: 18 Years and older
Enrollment: 247 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 15
States / cities: St. Petersburg, Florida • Columbus, Georgia • Macon, Georgia + 10 more

Search by objective public record fields.

A Study to Evaluate the Safety and Immunogenicity for Regimen Selection of Ad26.RSV.preF and/or RSV preF Protein Combinations Followed by Expanded Safety Evaluation in Adults Aged 60 Years and Older

A Study of TAK-951 in Healthy Adults

Randomized Placebo Controlled Trial of IVIg in Glycine Receptor Antibody Positive Stiff-person Syndrome

GWPCARE2 A Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P) in Children and Young Adults With Dravet Syndrome

An Observational Study Called FLAMINgO to Learn More About the Treatment Combination of Finerenone and SGLT2 Inhibitors in People With Long-term Kidney Disease (Chronic Kidney Disease) Together With Type 2 Diabetes by Using Routine Medical Care Data and Past Clinical Study Results

Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of GS-5745 (Andecaliximab) in Adults With Moderate to Severe Active Ulcerative Colitis

Study of IV Human Plasma-derived C1 Esterase Inhibitor Concentrate in Patients With Congenital C1-INH Deficiency for Treatment and Pre-procedure Preventing of Acute Hereditary Angioedema Attacks

A Single and Multiple Ascending Dose Study of Niclosamide in Healthy Volunteers

Simvastatin Augmentation of Lithium Treatment in Bipolar Depression

Linaclotide Safety and Efficacy in 2 to 5-Year-Old Participants With Functional Constipation

Study of ISIS 678354 (AKCEA-APOCIII-LRx) in Participants With Hypertriglyceridemia and Established Cardiovascular Disease (CVD)

Study of Difluprednate in the Treatment of Inflammation Following Ocular Surgery (ST-601A-002b)

The MIGHT Trial - An Exploratory Clinical Trial of IVIG in Anti-HMGCR Immune Mediated Necrotizing Myopathy

A Study to Evaluate the Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of TAK-079 in Combination With Standard Background Therapy in Participants With Moderate to Severe Systemic Lupus Erythematosus (SLE)

A Study of TAK-951 in Healthy Adults

ADP101 for Oral Immunotherapy in Food-Allergic Children and Adults

Omega-3 Replacement With Krill Oil in Disease Management of SLE

Intra-Erythrocyte Dexamethasone Sodium Phosphate in Ataxia Telangiectasia Patients

Phase I Study to Determine the Optimal Human Challenge Dose for a Norovirus GII.4 Challenge Stock (CIN-1)

Safety and Efficacy of Preoperative Antithrombin Supplementation in Patients Undergoing High-Risk Cardiopulmonary Bypass

Study to Evaluate the Safety & Tolerability of MRT5005 Administered by Nebulization in Adults With Cystic Fibrosis

Investigating the Anti-Human Immunodeficiency Virus (HIV) & Anti-inflammatory Effect of Chloroquine

A Placebo-controlled Safety and Tolerability Study of Intravenous (IV) and Subcutaneous (SC) AZD1163 in Healthy Volunteers

Double-blind, Randomized, Placebo-controlled, Prospective Phase III Study Evaluating Efficacy and Safety of Panzyga in Primary Infection Prophylaxis in Patients With Chronic Lymphocytic Leukemia ("PRO-SID" Study)